Recent research challenges the effectiveness of medicinal cannabis in treating mental health issues such as anxiety, depression, and PTSD. As cannabis use for medical purposes becomes increasingly common--reported by about 27% of individuals aged 16-65 in the U.S. and Canada--this study raises critical questions regarding its approval for mental health conditions.
Dr. Jack Wilson, the lead author from the University of Sydney's Matilda Centre, highlighted that the findings suggest medicinal cannabis could potentially worsen mental health outcomes. "While our study did not specifically address this, the routine use of medicinal cannabis may lead to a higher risk of psychotic symptoms and the development of cannabis use disorder, delaying the implementation of more effective treatments," he noted.
Limited Evidence for Alternative Conditions
Although some indications exist that medicinal cannabis might benefit certain conditions, such as cannabis use disorder, autism, insomnia, and Tourette's syndrome, Dr. Wilson cautioned that the supporting evidence remains weak. "The overall quality of evidence for these uses is low, and without robust medical or counseling support, the justification for using medicinal cannabis in these cases is rare," he explained.
Dr. Wilson also pointed out that while there is evidence supporting the use of medicinal cannabis for specific health issues like reducing seizures in epilepsy or managing pain, the study confirms a lack of solid evidence for mental health disorders.
Mixed Outcomes for Substance Use Disorders
The research also examined the impact of medicinal cannabis on various substance use disorders, revealing mixed results. Treatments derived from cannabis have shown potential benefits for cannabis dependence, yet concerning effects were noted for individuals with cocaine-use disorder, where cannabis use heightened cravings.
"Similar to the use of methadone in treating opioid dependence, cannabis medicines may effectively aid those with cannabis-use disorder when combined with psychological therapy," Dr. Wilson stated. "However, its use for treating cocaine dependence appears counterproductive, as it may exacerbate cravings."
Advocating for Stronger Regulation
The surge in medicinal cannabis prescriptions has prompted concerns among major medical organizations, including the American Medical Association, regarding the need for stronger regulations and clarity on the safety and effectiveness of these products. Dr. Wilson emphasized, "Our study provides a thorough and independent evaluation of cannabis medicines, aiding clinicians in making informed decisions to ensure patients receive effective treatments while minimizing potential harm from ineffective products."
A Comprehensive Global Analysis
This study is based on a systematic review and meta-analysis of 54 randomized controlled trials conducted globally over a span of 45 years (1980-2025). Funded by NHMRC, the research underscores the necessity for ongoing scrutiny in the evolving landscape of medicinal cannabis.